KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biomarin Pharmaceutical (BMRN) Leases (2019 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Leases for 11 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 85.89% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2025, down 85.89%, and an annual FY2025 reading of $4.0 million, down 85.89% over the prior year.
  • Leases was $4.0 million for Q4 2025 at Biomarin Pharmaceutical, down from $28.7 million in the prior quarter.
  • Across five years, Leases topped out at $38.2 million in Q4 2021 and bottomed at $3.3 million in Q4 2023.
  • Average Leases over 5 years is $16.1 million, with a median of $6.0 million recorded in 2022.
  • The sharpest move saw Leases soared 757.91% in 2024, then crashed 85.89% in 2025.
  • Year by year, Leases stood at $38.2 million in 2021, then plummeted by 84.24% to $6.0 million in 2022, then crashed by 44.48% to $3.3 million in 2023, then skyrocketed by 757.91% to $28.7 million in 2024, then tumbled by 85.89% to $4.0 million in 2025.
  • Business Quant data shows Leases for BMRN at $4.0 million in Q4 2025, $28.7 million in Q4 2024, and $3.3 million in Q4 2023.